Split Indication Deals Are Lose-Lose For Partnering Firms, Boehringer Says
Executive Summary
Companies should be wary of split indication agreements for products due to the complexities of such deals in practice, Boehringer Ingelheim Alliance Management Director Brooke Paige said Aug. 9